Silence Therapeutics PLC Cash Flow Reinvestment Rate
Silence Therapeutics PLC cash flow reinvestment rate. Silence Therapeutics PLC (SLN) has a Cash Flow Reinvestment Rate of 43.45x as of June 2026, reinvesting $64.94 Million (capex $3.00 plus investments $64.94 Million) from operating cash flow of $1.49 Million. Explore SLN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Silence Therapeutics PLC (2019–2021)
Cash flow reinvestment rate of Silence Therapeutics PLC from 2019 to 2021. Historical reinvestment intensity for Silence Therapeutics PLC across 2 annual periods. Explore SLN capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Silence Therapeutics PLC Cash Flow Reinvestment Rate by Year (2019–2021)
Silence Therapeutics PLC cash flow reinvestment rate by year from 2019 to 2021. Year-by-year capital reinvestment analysis for Silence Therapeutics PLC. For the full cash flow conversion analysis, see cash efficiency ratio of Silence Therapeutics PLC.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.28x | $11.80 Million | $9.19 Million | $1.80 Million | ▼ -85.2% |
| 2019 | 8.70x | $15.02 Million | $1.73 Million | $9.00K | — |